Amneal Pharmaceuticals
Search results
Apr 10, 2024 · For more than three decades, Acadia has been at the forefront of healthcare, elevating lives by providing essential solutions to those who need them most. We pioneered the first and only approved therapies for hallucinations and delusions in Parkinson’s disease psychosis and Rett syndrome.
Our 500+ employees in San Diego, CA, Princeton, NJ and people around the world fight diseases to help brighter moments shine through for patients and their loved ones. We embrace our mission and values, so we can continue to develop innovative therapies for those who need it most.
Mar 10, 2023 · Acadia Pharmaceuticals Announces U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatric Patients Two Years of Age and Older. — First and only approved therapy for Rett syndrome, a rare, neurodevelopmental disorder, which affects 6,000 to 9,000 patients in the U.S.1.
May 15, 2020 · Join a team united by a shared passion to innovate treatments and solutions and elevate life through science. Search for a career at Acadia.
Find the latest ACADIA Pharmaceuticals Inc. (ACAD) stock quote, history, news and other vital information to help you with your stock trading and investing.
Mar 11, 2024 · SAN DIEGO--(BUSINESS WIRE)--Mar. 11, 2024-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line results from the Phase 3 ADVANCE-2 trial evaluating pimavanserin for the treatment of negative symptoms of schizophrenia.
6 days ago · At Acadia, we remain deeply committed to providing important new therapies to patients and delivering value for our stockholders. Our Investor Center is designed to provide you with convenient access to company information.
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Sorrento Valley, San Diego, California. [2]
Jul 18, 2022 · SAN DIEGO -- (BUSINESS WIRE)--Jul. 18, 2022-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for trofinetide for the treatment of Rett syndrome in adults and pediatric patients two years of age and older.
Acadia Pharmaceuticals Inc. | 75,847 followers on LinkedIn. Acadia is trailblazing breakthroughs in neuroscience to elevate life. | Our Acadia family of care-ageous warriors aspire to...
